By Chris Wack
Shares of ChromaDex were up 56% to $8.73 after the company reported fourth-quarter earnings that beat analysts expectations.
The bioscience company said it had quarterly earnings of $7.2 million, or nine cents a share, compared with earnings of $114,000, or zero cents a share, in the same quarter last year. Analysts polled by FactSet were looking for earnings of $1.7 million, or two cents a share.
Sales for the quarter were $29.1 million, compared with last year's $21.2 million and the $26.8 million analysts were expecting.
The company said sales of its lead product, Tru Niagen, rose 29% from a year earlier, primarily from e-commerce.
ChromaDex is forecasting an 18% increase in sales for 2025.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 05, 2025 12:28 ET (17:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.